1. Introduction
COVID-19, a novel pathogenic coronavirus (2019-nCoV or SARS-CoV2) induced disease, emerged in China and spread globally rapidly.
GeneMedi produces kinds of recombinant 2019 nCoV(SARS2 coronavirus) antigens as shown below: Nucleocapsid(N protein), Spike(S protein), RBD, S1+S2 ECD, Envelope (E protein), 3C-like Proteinase. All the recombinant proteins of 2019 nCoV are suitable for in functional ELISA,lateral-flow tests, and other immunoassays.
GeneMedi has submitted a preprints review about COVID-19 and 2019-nCoV.
Click here for the full-text reading:
Viral vector-based vaccine; DNA-based vaccine; RNA based vaccine – A landscape for vaccine technology against infectious disease, COVID-19 and tumor.
An Insight of comparison between COVID-19 (2019-nCoV disease) and SARS in pathology and pathogenesis
Landscape Coronavirus Disease 2019 test (COVID-19 test) in vitro — A comparison of PCR vs Immunoassay vs Crispr-Based test
In the mission of helping global scientists for the development of diagnosis and drug against 2019 nCoV(SARS2 coronavirus), GeneMedi scientists will keep moving.
2. Protocol & primers $ probes collection for Real-time (rRT-PCR) Panel based COVID-19 (2019 nCoV, SARS2 coronavirus) detection.
- 2019 nCoV peiris-detection protocol-16-1-20-HKU
- 2019-Novel Coronavirus (2019-nCoV) Real-time rRT-PCR Panel Primers and Probes-USCDC
- China CDC 2019-nCoV detection primer
- Construction_of_Lentivirus-Based_Reference_Materia
- Diagnostic detection of Wuhan coronavirus 2019 by real-time RT-PCR – Charité, Berlin Germany
- uscdcrt-pcr-panel-primer-probes